David Easty

Summary

Affiliation: University College Dublin
Country: Ireland

Publications

  1. ncbi Up-regulation of ephrin-A1 during melanoma progression
    D J Easty
    St George s Hospital Medical School, London, UK
    Int J Cancer 84:494-501. 1999
  2. ncbi Protein tyrosine kinases in malignant melanoma
    D J Easty
    Department of Pathology, University College Dublin, Ireland
    Melanoma Res 10:401-11. 2000
  3. ncbi Protein tyrosine phosphatases, new targets for cancer therapy
    David Easty
    Department of Pathology, Conway Institute, University College Dublin, Dublin, Ireland
    Curr Cancer Drug Targets 6:519-32. 2006
  4. ncbi Receptor tyrosine kinases and their activation in melanoma
    David J Easty
    Department of Oncology, St James s Hospital, Dublin, Ireland Division of Biomedical Sciences, St George s, University of London, London, UK
    Pigment Cell Melanoma Res 24:446-61. 2011

Detail Information

Publications4

  1. ncbi Up-regulation of ephrin-A1 during melanoma progression
    D J Easty
    St George s Hospital Medical School, London, UK
    Int J Cancer 84:494-501. 1999
    ..Both effects may be potentiated by inflammatory responses. Our data are consistent with earlier observations that an inflammatory infiltrate is associated with poor prognosis in thin primary melanomas...
  2. ncbi Protein tyrosine kinases in malignant melanoma
    D J Easty
    Department of Pathology, University College Dublin, Ireland
    Melanoma Res 10:401-11. 2000
    ..In addition, PTKs expressed in significant amounts in both benign and malignant melanocytes, such as insulin-like growth factor-1 receptor (IGF1-R), FGF-R1, HER2/NEU and FAK, are likely to play a role in melanoma genesis and progression...
  3. ncbi Protein tyrosine phosphatases, new targets for cancer therapy
    David Easty
    Department of Pathology, Conway Institute, University College Dublin, Dublin, Ireland
    Curr Cancer Drug Targets 6:519-32. 2006
    ..Finally, we address the role of PTPs in melanoma, an increasingly common tumour that may represent an appropriate target for therapeutic manipulation of PTP activity...
  4. ncbi Receptor tyrosine kinases and their activation in melanoma
    David J Easty
    Department of Oncology, St James s Hospital, Dublin, Ireland Division of Biomedical Sciences, St George s, University of London, London, UK
    Pigment Cell Melanoma Res 24:446-61. 2011
    ..Kinases are considered druggable targets, so characterization of global RTK activity in melanoma should assist the rational development of tyrosine kinase inhibitors for clinical use...